$ABBV

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.

Schwab's dividend ETF ($SCHD) combines 3.1% yield with strict quality filters, averaging 12.5% annual returns over ten years through defensive sector exposure.

CVS and AbbVie emerge as recovery opportunities post-market pullback, leveraging diversified operations and immunology momentum respectively, with strong dividend backing investor confidence.

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.

FDA approves Icotyde for psoriasis, triggering $50M payment to Protagonist. Market reacts with AbbVie stock falling 5.20% amid competitive pressure.

CollPlant Biotechnologies launches redesigned website showcasing plant-derived collagen technology, product pipeline, and investor resources to enhance market transparency and stakeholder engagement.

AbbVie, Walmart, and Consolidated Edison emerge as top dividend plays for March 2026, each boasting 50+ years of consecutive dividend increases.

Vestal Point Capital sold $103.93M in Nuvalent shares, reducing exposure despite company's 30% rally and $1.4B cash position awaiting 2026 FDA decisions.

Five dividend stocks and ETFs offer yields ranging from 2.6% to 10.6%, spanning REITs, energy, pharma, consumer staples, and covered-call strategies for diversified income.

Concorde Financial completely exits $4.28M stake in Howard Hughes Holdings, liquidating entire 2.4% portfolio position in master-planned community developer.

Dividend Kings Johnson & Johnson and AbbVie offer 50+ years of consecutive dividend growth with resilient pipelines successfully offsetting patent expirations.

AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.

Three firms—Gilead Sciences, AbbVie, and Visa—offer defensive portfolios substantial free cash flow yields and capital returns amid 2026 market uncertainty.

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

AbbVie's Skyrizi achieved 55% remission rate in Crohn's patients versus 30% placebo, strengthening competitive positioning against Johnson & Johnson's Tremfya.

BMS's Sotyktu shows promise for psoriatic arthritis among one-third of surveyed rheumatologists, but analysts expect modest market capture ahead of March 2026 FDA decision.

Established large-cap companies like Caterpillar and Oracle gain as investors rotate away from mega-cap tech, seeking dividend payers with strong balance sheets and consistent earnings.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.